Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 16/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277748 | 0.87 | OPRL1 (0.44) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL10060840 | 0.83 | OPRL1 (0.68) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL7815717 | 0.83 | OPRL1 (0.68) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL11188082 | 0.79 | OPRL1 (0.42) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL3876399 | 0.78 | OPRM1 (0.50) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3126817 | 0.78 | OPRM1 (0.46) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3640272 | 0.78 | OPRM1 (0.46) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL216848 | 0.78 | DRD2 (0.60) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL1724862 | 0.78 | OPRL1 (0.57) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL1109741 | 0.78 | OPRL1 (0.57) | OPRL1OPRM1OPRK1OPRD1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111362933-A | α -amino acrylic acid microbicide and preparation method and application thereof | 南开大学 | 2020-07-03 | — | — | CN | claimed |
| US-7939534-B2 | e.g. (2-{[2-(3-fluorophenyl)ethyl]amino}-6-piperidyl(3-pyridyl))-N-(3-pyridylmethyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, chronic obstructive pulmonary disease, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-05-10 | — | — | US | claimed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-7576217-B2 | Quinolines as allosteric enhancers of the GABAB receptors | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | claimed |
| US-7544675-B2 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | UCB, S.A. (BE) | 2009-06-09 | — | — | US | claimed |
| US-20090062277-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. | 2009-03-05 | — | — | US | claimed |
| US-20080139575-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-06-12 | — | — | US | claimed |
| US-20060094754-A1 | Quinolines as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-05-04 | — | — | US | claimed |
| US-20060074068-A1 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | UCB, S.A. (BE) | 2006-04-06 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| EP-0178946-A2 | 1-(Aminoalkyl)-alpha, alpha-diaryl pyrrolidine-piperidine- and homopiperidine- acetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-04-23 | — | — | EP | claimed |
| EP-0178947-A2 | 1-[(Aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-alpha,alpha-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-04-23 | — | — | EP | claimed |
| US-4558155-A | N-(Aryloxyalkyl)-N'-(aminoalkyl)thioureas | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-12-10 | — | — | US | claimed |
| EP-0160436-A2 | N-[(Amino)Alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulphur linked substitution in the 2, 3 or 4-position | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-11-06 | — | — | EP | claimed |
| US-4500529-A | ANTIARRHYTHMIA AGENT | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-02-19 | — | — | US | claimed |
| US-4171361-A | HYPOTENSIVE | ELI LILLY AND COMPANY (US) | 1979-10-16 | — | — | US | claimed |
| US-4110536-A | ANTIARRHYTHMIA | MILES LABORATORIES, INC. (US) | 1978-08-29 | — | — | US | claimed |
| US-4045442-A | ANTIINFLAMMATORY, ANTIDIARRHEA | G. D. SEARLE & CO. (US) | 1977-08-30 | — | — | US | claimed |
| US-4017491-A | 1,1-Diaryl-1H-tetrazole amines | G. D. SEARLE & CO. (US) | 1977-04-12 | — | — | US | claimed |
| US-4006232-A | Therapeutic method of treating cardiac arrhythmias utilizing 3-substituted diphenylhydantoins | MILES LABORATORIES, INC. (US) | 1977-02-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139575-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | OPRL1 2444/4885OPRM1 1013/4885OPRK1 2189/4885 |
| US-20060074068-A1 | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | PDE7A, CHRM3, PDE4B | OPRL1 1161/4885OPRM1 200/4885OPRK1 376/4885 |
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | OPRL1 1195/4885OPRM1 670/4885OPRK1 494/4885 |
| US-20060094754-A1 | Quinolines as allosteric enhancers of the GABAB receptors | GABRB1, GABRB2, GABRA1 | OPRL1 71/4885OPRM1 181/4885OPRK1 82/4885 |
| US-20090062277-A1 | PHOSPHODIESTERASE 10 INHIBITORS | PDE5A, PDE12, PDE10A | OPRL1 1140/4885OPRM1 2663/4885OPRK1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.